SOURCE: Arch Therapeutics, Inc.

Arch Therapeutics, Inc.

November 10, 2014 08:57 ET

Arch Therapeutics Will Present at Two Investor Conferences in November

WELLESLEY, MA--(Marketwired - Nov 10, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™, announced that it would be featured as a presenting company at two conferences in November: SeeThruEquity Microcap Investor Conference and Drexel Hamilton Micro-Cap Investor Forum.

In addition to providing a corporate overview, Chief Executive Officer, Terrence W. Norchi, MD, will discuss the importance of a hemostatic agent that is effective in patients prescribed medications commonly referred to as "blood thinners," in light of the recent positive studies of AC5™ in animals on the anticoagulant medication heparin and in animals on the antiplatelet therapies aspirin and Plavix® (clopidogrel).

The current presentation will be available on the corporate website (www.archtherapeutics.com).

SeeThruEquity Microcap Investor Conference
Arch Therapeutics will be featured on Wednesday, November 12, 2014 at 1:30 PM at Bryan Park Hub, New York, NY.

Drexel Hamilton Micro-Cap Investor Forum
Arch Therapeutics will be featured on Thursday, November 13, 2014 at 9:30 AM at the Drexel Hamilton Offices, 77 Water Street, New York, NY.

About Arch Therapeutics, Inc.

Arch Therapeutics, Inc. is a medical device company developing a novel approach to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. Arch is developing products based on an innovative self-assembling peptide technology platform to make surgery and interventional care faster and safer for patients. Arch's flagship development stage product candidate, known as the AC5 Surgical Hemostatic Device ™, is being designed to achieve hemostasis in minimally invasive and open surgical procedures.

Notice Regarding Forward-Looking Statements

This news release contains "forward-looking statements" as that term is defined in Section 27(a) of the Securities Act of 1933, as amended, and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements in this press release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, references to novel technologies and methods, our business and product development plans and projections, or market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with developing new products or technologies and operating as a development stage company, our ability to retain important members of our management team and attract other qualified personnel, our ability to raise the additional funding we will need to continue to pursue our business and product development plans, our ability to develop and commercialize products based on our technology platform, and market conditions. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the reports and other documents we file with the SEC, available at www.sec.gov.

On Behalf of the Board,
Terrence W. Norchi, MD
Arch Therapeutics, Inc.

Contact Information